查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1166107

肌肉萎縮性脊髓側索硬化症(ALS)治療的全球市場 - 成長，未來展望，競爭分析(2022年～2030年)

Amyotrophic Lateral Sclerosis (ALS) Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格

肌肉萎縮性脊髓側索硬化症(ALS)的發病率增加，強力的開發平台分子，部分國家的有利的償付政策，預期新藥的銷售，治療意識的高漲，老年人口增加等要素，預計促進肌肉萎縮性脊髓側索硬化症(ALS)治療市場全球性成長。

本報告提供全球肌肉萎縮性脊髓側索硬化症(ALS)治療市場相關調查，市場趨勢，競爭資訊，市場區隔分析，新興趨勢，技術分析，企業簡介等資訊。

目錄

第1章 序文

  • 報告的說明
  • 市場區隔
  • 調查手法

第2章 摘要整理

  • 市場概述:全球肌肉萎縮性脊髓側索硬化症(ALS)治療市場
  • 全球肌肉萎縮性脊髓側索硬化症(ALS)治療市場:各藥物(2021年)
  • 全球肌肉萎縮性脊髓側索硬化症(ALS)治療市場:各地區(2021年)
  • COVID-19影響
  • 富有魅力的投資提案:各地區(2021年)
  • 競爭分析
    • 主要的肌肉萎縮性脊髓側索硬化症(ALS)治療市場供應商的市場定位
    • 肌肉萎縮性脊髓側索硬化症(ALS)治療市場供應商採用的策略
    • 主要的產業策略

第3章 肌肉萎縮性脊髓側索硬化症(ALS)治療市場:商務的預測與市場動態

  • 簡介
  • 全球肌肉萎縮性脊髓側索硬化症(ALS)治療市場金額(2020年～2030年)
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要的機會
  • 促進因素、阻礙因素的影響分析
  • See-Saw分析
  • 波特的五力分析
  • PESTEL分析

第4章 肌肉萎縮性脊髓側索硬化症(ALS)治療市場:各藥物(2020年～2030年)

  • 市場概要
  • 成長和收益分析:2021年對2030年
  • 市場區隔
    • Riluzole
    • Edaravone
    • 其他

第5章 北美的肌肉萎縮性脊髓側索硬化症(ALS)治療市場(2020年～2030年)

  • 市場概要
  • 肌肉萎縮性脊髓側索硬化症(ALS)治療市場:各藥物(2020年～2030年)
  • 肌肉萎縮性脊髓側索硬化症(ALS)治療市場:各地區(2020年～2030年)
    • 北美

第6章 英國、歐洲聯盟的肌肉萎縮性脊髓側索硬化症(ALS)治療市場(2020年～2030年)

  • 市場概要
  • 肌肉萎縮性脊髓側索硬化症(ALS)治療市場:各藥物(2020年～2030年)
  • 肌肉萎縮性脊髓側索硬化症(ALS)治療市場:各地區(2020年～2030年)
    • 英國、歐洲聯盟

第7章 亞太地區的肌肉萎縮性脊髓側索硬化症(ALS)治療市場(2020年～2030年)

  • 市場概要
  • 肌肉萎縮性脊髓側索硬化症(ALS)治療市場:各藥物(2020年～2030年)
  • 肌肉萎縮性脊髓側索硬化症(ALS)治療市場:各地區(2020年～2030年)
    • 亞太地區

第8章 南美的肌肉萎縮性脊髓側索硬化症(ALS)治療市場(2020年～2030年)

  • 市場概要
  • 肌肉萎縮性脊髓側索硬化症(ALS)治療市場:各藥物(2020年～2030年)
  • 肌肉萎縮性脊髓側索硬化症(ALS)治療市場:各地區(2020年～2030年)
    • 南美

第9章 中東、非洲的肌肉萎縮性脊髓側索硬化症(ALS)治療市場(2020年～2030年)

  • 市場概要
  • 肌肉萎縮性脊髓側索硬化症(ALS)治療市場:各藥物(2020年～2030年)
  • 肌肉萎縮性脊髓側索硬化症(ALS)治療市場:各地區(2020年～2030年)
    • 中東、非洲

第10章 企業簡介

  • AB Science
  • Avicena Group
  • Biogen
  • BrainStorm Therapeutics
  • Covis Pharmaceutical Inc.
  • Cytokinetics Inc.
  • Eisai Co. Ltd.
  • GlaxoSmithKline plc.
  • Ionis Pharmaceuticals, Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Neuralstem Inc.
  • Neuraltus Pharmaceuticals Inc.
  • Newron Pharmaceuticals S.p.A.
  • Pharnext SAS
  • Q-Therapeutics Inc.
Product Code: 137607-08-22

Amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease is a neurological disease that causes death of nerve cells that control voluntary muscles. Factors such, increase in incidence of ALS, strong pipeline molecule, favorable reimbursement policies in some countries and expected launch of newer medication would drive the growth of ALS treatment market globally.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, opportunities and pipeline analysis assists the readers for understanding the ongoing trends in the global ALS treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global ALS treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global ALS treatment market. In-depth competitive environment analysis and historical years (2021) market size data are also provided in the report.

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig's disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die. According to Centers for Disease Control and Prevention (CDC), 14,000 - 15,000 Americans had ALS in 2016. Factors such as increasing treatment awareness, strong pipeline molecules, rising geriatric population and recent approval of new treatment medication is expected to drive the growth of ALS treatment market globally. Currently, there is no cure for ALS however, treatments are available to control symptoms and prevent unnecessary complications. The U.S. Food and Drug Administration (FDA) has approved only two drugs for the treatment of ALS it includes Riluzole (Rilutek) and Edaravone (Radicava). Other medications are prescribe to control ALS symptoms such as muscle cramps and spasms, spasticity, constipation, fatigue, excessive salivation, excessive phlegm, pain, depression and sleep problems. It is studied that in the base year 2016, Riluzole (Rilutek) was major revenue generating segment due to high compliance because it is the only medication used in treatment of ALS which works by reducing levels of a chemical messenger in the brain (glutamate) that often present in higher levels in people with ALS. Patent expiry of Rilutek in 2013 has negatively impacted the growth of ALS treatment market. On the other hand, recently approve Radicava expected to show highest growth rate during forecast period due to its applicability and higher cost are expected to drive market growth during forecast period. Moreover expected launch of ALS treatment molecule such as AB-1010 (masitinib), Methycobal (mecobalamin), Arimoclomol, CK-2017357 (CK-357, tirasemtiv) would assist market growth during forecast period.

It is observed that, in the base year 2016, North America dominated the ALS treatment market in terms of revenue due to the factors such as upsurge in funding by government agencies and private organizations in healthcare system, increase in prevalence of the neurological diseases and higher treatment awareness are assisting market growth in North America. According to National ALS Registry, in year 2016, more than 12,000 people in the United States have a definite diagnosis of ALS, prevalence of 3.9 cases per 100,000 persons in the U.S. general population. According to National Organization for Rare Disorders (NORD), ALS is a rare disorder, approximately 5,000 new cases are diagnosed each year in the United States. Even though Riluzole is expensive, insurance policies such as Medicare, also the National Organization for Rare Diseases also support covers Riluzole. Furthermore Covis Patient Assistance Program helps U.S. citizens or residents who don't have a health care plan or have been denied coverage for treatment which is further driving the market growth in North America. It is estimated that, Asia Pacific will show highest growth rate during forecast period due to increasing healthcare awareness, increasing partnership of key players such as Biogen, Avicena, Mitsubishi Tanabe, and Sanofi with local manufacturer, populous countries and developing economic condition would fuel ALS treatment market growth.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Amyotrophic Lateral Sclerosis (ALS) Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Amyotrophic Lateral Sclerosis (ALS) Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug

Riluzole

Edaravone

Other

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Million )

Pre Covid-19 situation

Post Covid-19 situation

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Amyotrophic Lateral Sclerosis (ALS) Treatment market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Amyotrophic Lateral Sclerosis (ALS) Treatment market?

Which is the largest regional market for Amyotrophic Lateral Sclerosis (ALS) Treatment market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Amyotrophic Lateral Sclerosis (ALS) Treatment market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Amyotrophic Lateral Sclerosis (ALS) Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  • 2.2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Drug, 2021 (US$ Million)
  • 2.3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Geography, 2021 (US$ Million)
  • 2.4. Impact of Covid 19
  • 2.5. Attractive Investment Proposition by Geography, 2021
  • 2.6. Competitive Analysis
    • 2.6.1. Market Positioning of Key Amyotrophic Lateral Sclerosis (ALS) Treatment Market Vendors
    • 2.6.2. Strategies Adopted by Amyotrophic Lateral Sclerosis (ALS) Treatment Market Vendors
    • 2.6.3. Key Industry Strategies

3. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Riluzole
    • 4.3.2. Edaravone
    • 4.3.3. Other

5. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2020-2030, USD (Million)
  • 5.3.Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Region, 2020-2030, USD (Million)
    • 5.3.1.North America
      • 5.3.1.1. U.S.
      • 5.3.1.2. Canada
      • 5.3.1.3. Rest of North America

6. UK and European Union Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2020-2030, USD (Million)
  • 6.3.Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.UK and European Union
      • 6.3.1.1. UK
      • 6.3.1.2. Germany
      • 6.3.1.3. Spain
      • 6.3.1.4. Italy
      • 6.3.1.5. France
      • 6.3.1.6. Rest of Europe

7. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2020-2030, USD (Million)
  • 7.3.Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.Asia Pacific
      • 7.3.1.1. China
      • 7.3.1.2. Japan
      • 7.3.1.3. India
      • 7.3.1.4. Australia
      • 7.3.1.5. South Korea
      • 7.3.1.6. Rest of Asia Pacific

8. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2020-2030, USD (Million)
  • 8.3.Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Latin America
      • 8.3.1.1. Brazil
      • 8.3.1.2. Mexico
      • 8.3.1.3. Rest of Latin America

9. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2020-2030, USD (Million)
  • 9.3.Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Middle East and Africa
      • 9.3.1.1. GCC
      • 9.3.1.2. Africa
      • 9.3.1.3. Rest of Middle East and Africa

10. Company Profile

  • 10.1. AB Science
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Initiatives
  • 10.2. Avicena Group
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Initiatives
  • 10.3. Biogen
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Portfolio
    • 10.3.4. Strategic Initiatives
  • 10.4. BrainStorm Therapeutics
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Initiatives
  • 10.5. Covis Pharmaceutical Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Initiatives
  • 10.6. Cytokinetics Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
    • 10.6.4. Strategic Initiatives
  • 10.7. Eisai Co. Ltd.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Portfolio
    • 10.7.4. Strategic Initiatives
  • 10.8. GlaxoSmithKline plc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Portfolio
    • 10.8.4. Strategic Initiatives
  • 10.9. Ionis Pharmaceuticals, Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Portfolio
    • 10.9.4. Strategic Initiatives
  • 10.10. Mitsubishi Tanabe Pharma Corp.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Initiatives
  • 10.11. Neuralstem Inc.
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Portfolio
    • 10.11.4. Strategic Initiatives
  • 10.12. Neuraltus Pharmaceuticals Inc.
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Portfolio
    • 10.12.4. Strategic Initiatives
  • 10.13. Newron Pharmaceuticals S.p.A.
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Portfolio
    • 10.13.4. Strategic Initiatives
  • 10.14. Pharnext SAS
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Portfolio
    • 10.14.4. Strategic Initiatives
  • 10.15. Q-Therapeutics Inc.
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Portfolio
    • 10.15.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 3 UK and European Union Amyotrophic Lateral Sclerosis (ALS) Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 4 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 5 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 6 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market By Drug, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Quality Assurance
  • FIG. 5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Drug, 2021
  • FIG. 6 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Geography, 2021
  • FIG. 7 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Drug, 2021 Vs 2030, %
  • FIG. 8 U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 9 Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 10 Rest of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 11 UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 France Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 India Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 Rest of Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 GCC Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market (US$ Million), 2020 - 2030